Lynch综合征相关上尿路尿路上皮癌的基因型-表型特征
该单中心回顾性研究分析了37例确诊Lynch综合征(LS)并发生上尿路尿路上皮癌(UTUC)的患者,按胚系MMR基因突变分层并与散发性UTUC比较。MSH6突变者发病年龄更大(68.5岁 vs MSH2突变者58.0岁),既往LS相关癌症史更少,低级别肿瘤更多见;LS-UTUC双侧病变更常见(23% vs 散发性8%)。90%胚系MMR突变患者免疫组化显示MMR蛋白表达缺失。
要点
- MSH6突变相关UTUC发病年龄较大且癌症个人史/家族史较少,年龄不宜作为LS检测的排除标准。
- LS-UTUC双侧病变比例高于散发性UTUC(23% vs 8%),双侧病变应警惕LS。
- 90%胚系MMR突变患者免疫组化显示MMR蛋白表达缺失,与基因检测高度一致。
核心结论
- MSH6胚系突变相关UTUC发病年龄较大且癌症史较少,对年龄作为LS检测判别标准提出质疑。
- 任何新诊断UTUC尤其双侧病变应启动LS筛查或胚系检测。
研究设计与样本
- 单中心回顾性研究,纳入37例确诊LS并UTUC的患者,按胚系MMR基因突变分层并与散发性UTUC比较。
- 收集肿瘤免疫组化及PCR微卫星不稳定性数据。
主要发现
- 37例LS-UTUC中,MSH2突变25例、MSH6突变8例、MLH1突变3例、PMS2突变1例。
- MSH6突变者发病年龄68.5岁,MSH2突变者58.0岁。
- MSH6突变者既往LS相关癌症史更少,低级别肿瘤更多见。
- LS-UTUC双侧病变占23%,散发性UTUC占8%。
- 90%胚系MMR突变患者免疫组化显示MMR蛋白表达缺失。
关键数值与推荐
- LS-UTUC双侧病变比例23%,散发性UTUC为8%。
- 胚系MMR突变患者中90%免疫组化显示MMR蛋白表达缺失。
临床怎么用
- 对新诊断UTUC尤其双侧病变患者,应进行LS筛查或胚系检测。
- 不应仅因年龄较大而排除LS检测,尤其MSH6突变者发病年龄较晚。
- 免疫组化MMR蛋白表达缺失与胚系突变高度一致,可作为筛查工具。
局限性
- 单中心回顾性研究,样本量较小(37例LS-UTUC)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Upper tract urothelial carcinoma (UTUC) is the most prevalent urologic malignancy among patients with Lynch syndrome (LS), which is caused by germline mutations in genes MSH2, MSH6, MLH1, and PMS2 involved in DNA mismatch repair (MMR). We describe clinical phenotypes of UTUC by MMR genotype and in comparison to sporadic UTUC. METHODS: Data for patients with confirmed LS and UTUC treated at a single cancer center were retrospectively reviewed. Patients were stratified by their underlying gene mutations and compared to patients with sporadic UTUC. Data on tumor immunohistochemistry (IHC) and microsatellite instability status on polymerase chain reaction were collected. KEY FINDINGS AND LIMITATIONS: Of 37 patients with LS-UTUC, 25 had germline MSH2 mutations, eight had MSH6 mutations, three had MLH1 mutations, and one had a PMS2 mutation. Patients with MSH6 mutations were older (68.5 yr) at presentation than patients with MSH2 mutations (58.0 yr), were less likely to have had prior LS-associated cancers, and were more likely to present with low-grade tumors. Bilateral disease was more common in LS-UTUC (23%) than in sporadic UTUC (8%). IHC analysis revealed strong concordance with germline alterations: 90% of patients with germline MMR mutations had deficient MMR protein expression. CONCLUSIONS AND CLINICAL IMPLICATIONS: Patients with germline MSH6 mutations tended to be older at LS-UTUC onset and were less likely to have a personal and family history of cancer in comparison to patients with germline MSH2 or MLH1 mutations, bringing into question age as a discriminatory criterion for testing. Any new diagnosis of UTUC, especially in cases with bilateral disease, should prompt screening or germline testing given the heterogeneous phenotypes associated with LS.
引用
- Labbate C, Igel DA, Saporito D, et al. Genotype-Phenotype Characterization of Lynch Syndrome-associated Upper Tract Urothelial Carcinoma. Eur Urol Oncol. 2025. PMID: 41176509. doi:10.1016/j.euo.2025.10.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。